Cutler Group’s Anika Therapeutics ANIK Stock Holding History

Cutler Group’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,000	Closed	-$35K	–	4620
2020 Q2	$35K	Hold	10,000	–	–	﹤0.01%	1999
2020 Q1	$101K	Sell	10,000 -7,500	-43%	-$303K	0.01%	1321
2019 Q4	$68K	Sell	17,500 -5,000	-22%	-$290K	﹤0.01%	1414
2019 Q3	$51K	Buy	+22,500	New	+$1.16M	﹤0.01%	1520
2017 Q2	–	Sell	-10,000	Closed	-$6K	–	6295
2017 Q1	$6K	Buy	10,000 +9,000	+900%	+$430K	﹤0.01%	4498
2016 Q4	$3K	Buy	+1,000	New	+$46.2K	﹤0.01%	5253
2016 Q3	–	Sell	-5,000	Closed	-$8K	–	6596
2016 Q2	$8K	Buy	5,000 +3,000	+150%	+$141K	﹤0.01%	4379
2016 Q1	$3K	Sell	2,000 -9,000	-82%	-$365K	﹤0.01%	5197
2015 Q4	$22K	Buy	+11,000	New	+$421K	﹤0.01%	3308

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cutler Group's ANIK Position: Q2 2020 in Review

Cutler Group sold out of Anika Therapeutics (ANIK) in Q2 2020, closing a stake of 5,538 shares — an estimated $182K sold.

Cutler Group first reported a position in ANIK in Q4 2015 and held it in 8 quarters. The position peaked at $160K in Q1 2020. 158 funds tracked by Wall St. Rank hold ANIK as of Q2 2020.

Cutler Group reported no remaining Anika Therapeutics position as of Q2 2020 after selling out during the quarter.
Cutler Group sold 5,538 Anika Therapeutics shares in Q2 2020, an estimated $182K.
Cutler Group first reported a position in Anika Therapeutics in Q4 2015 and held it in 8 quarters.
Cutler Group's Anika Therapeutics position peaked at $160K in Q1 2020.
158 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2020.

Based on Cutler Group's 13F filing for Q2 2020, filed 22 Jul 2020.